Ani Pharmaceuticals (ANIP) Preferred Stock Liabilities (2021 - 2025)

Ani Pharmaceuticals (ANIP) has 5 years of Preferred Stock Liabilities data on file, last reported at $24.8 million in Q2 2025.

• For the quarter ending Q2 2025, Preferred Stock Liabilities changed 0.0% year-over-year to $24.8 million; the trailing twelve-month figure through Jun 2025 stood at $24.8 million (changed 0.0% YoY), and the FY2024 full-year result was $24.8 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities was little changed at $24.8 million in Q2 2025, from $24.8 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $24.8 million in Q4 2021 to a low of $24.8 million in Q4 2021.
• A 5-year average of $24.8 million and a median of $24.8 million in 2021 frame the typical range for Preferred Stock Liabilities.
• Peak annual rise in Preferred Stock Liabilities reached 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
• Tracing ANIP's Preferred Stock Liabilities over 5 years: stood at $24.8 million in 2021, then changed by 0.0% to $24.8 million in 2022, then changed by 0.0% to $24.8 million in 2023, then changed by 0.0% to $24.8 million in 2024, then changed by 0.0% to $24.8 million in 2025.
• Business Quant data shows ANIP's Preferred Stock Liabilities at $24.8 million in Q2 2025, $24.8 million in Q1 2025, and $24.8 million in Q4 2024.